Is Questcor A Good Investment?
moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboardSee who Questcor is hiring next, click here to view […]
QCOR
Don’t Let Questcor’s Short Squeeze Fool You, Major Risk Remains
moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboardSee who Questcor is hiring next, click here to view […]
Questcor Pharmaceuticals Moves Up In Market Cap Rank, Passing GameStop
moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboardSee who Questcor is hiring next, click here to view […]
Questcor Announces Quarterly Cash Dividend
[PR Newswire] – ANAHEIM, Calif., Feb. 14, 2014 /PRNewswire/ — Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 … moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboardSee who Questcor is hiring next, click here to view […]
Questcor to Report Fourth Quarter and Full Year 2013 Financial Results on February 25, 2014
[PR Newswire] – ANAHEIM, Calif., Feb. 12, 2014 /PRNewswire/ — Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release fourth quarter and full year 2013 financial results on Tuesday, February … moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboardSee who Questcor is hiring next, click here to view […]
PropThink: QCOR Beat Down To Reverse; Synacthen Toxic To Infants, Not A Real Threat
[ACN Newswire] – By David MoskowitzShares of Questcor Pharmaceuticals (NASDAQ:QCOR) are under pressure Friday, down 10% in morning trading on news that unknown drug company Cerium Pharmaceuticals has received Orphan Drug … moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: QCOR Delivers Big Upside In 3Q; Acthar Prescribing & Reimbursement Remain In-Tact
[ACN Newswire] – By David MoskowitzQuestcor Pharmaceuticals (NASDAQ:QCOR) trounced 3Q 2012 earnings expectations, with reported revenues of $140.3M and adjusted EPS of $0.97 for the period. This compares to Wall Street … moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: In-Line Earnings Are Good Enough For More QCOR Upside
[ACN Newswire] – By David MoskowitzQuestcor Pharmaceuticals (NASDAQ:QCOR) is scheduled to report third quarter earnings Tuesday after the market closes, and the Wall Street Consensus expects revenues (mostly Acthar Gel) … moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: QCOR, KERX Could Break Through Technical Barriers On Improving Fundamentals
[ACN Newswire] – By David MoskowitzFor most mutual funds, tax-loss selling must be done by the end of Monday. As a result, pressure could come off names that have had big downturns earlier this year. We are focusing on … moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: QCOR Strengthening On Positive Clinical Data To Be Presented Soon
[ACN Newswire] – By David MoskowitzQuestcor Pharmaceuticals (NASDAQ:QCOR), to no one’s surprise, remains volatile. Notably, the stock hit an intraday low of $17.60 on October 5th, and closed Thursday 19.5% higher than … moreView todays social media effects on QCORView the latest stocks trending across Twitter. Click to view dashboard […]
